66.90
price down icon1.02%   -0.69
after-market 시간 외 거래: 67.18 0.28 +0.42%
loading
전일 마감가:
$67.59
열려 있는:
$67.8
하루 거래량:
2.57M
Relative Volume:
0.47
시가총액:
$210.86B
수익:
$54.07B
순이익/손실:
$7.04B
주가수익비율:
29.67
EPS:
2.255
순현금흐름:
$7.28B
1주 성능:
-1.63%
1개월 성능:
-10.72%
6개월 성능:
-13.61%
1년 성능:
-2.41%
1일 변동 폭
Value
$66.59
$67.91
1주일 범위
Value
$66.59
$68.40
52주 변동 폭
Value
$61.24
$87.67

아스트라제네카 ADR Stock (AZN) Company Profile

Name
명칭
Astrazeneca PLC
Name
전화
44 20 3749 5000
Name
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
직원
61,100
Name
트위터
@AstraZeneca
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
AZN's Discussions on Twitter

AZN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
66.90 210.86B 54.07B 7.04B 7.28B 2.255

아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-15 개시 Exane BNP Paribas Outperform
2025-02-13 업그레이드 UBS Neutral → Buy
2025-02-12 개시 Morgan Stanley Overweight
2024-11-20 업그레이드 UBS Sell → Neutral
2024-11-06 업그레이드 Deutsche Bank Sell → Hold
2024-09-13 다운그레이드 Deutsche Bank Hold → Sell
2024-05-30 개시 Goldman Buy
2024-04-16 업그레이드 Deutsche Bank Sell → Hold
2024-02-08 다운그레이드 Deutsche Bank Hold → Sell
2024-01-23 개시 Morgan Stanley Overweight
2024-01-16 재개 UBS Sell
2024-01-03 다운그레이드 Jefferies Buy → Hold
2023-12-18 개시 HSBC Securities Buy
2023-09-25 업그레이드 Jefferies Hold → Buy
2023-07-14 개시 HSBC Securities Buy
2023-07-12 업그레이드 UBS Neutral → Buy
2023-07-05 다운그레이드 Deutsche Bank Buy → Hold
2023-04-11 업그레이드 Morgan Stanley Equal-Weight → Overweight
2023-01-05 개시 BMO Capital Markets Outperform
2022-09-15 다운그레이드 Credit Suisse Outperform → Neutral
2022-09-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-08-29 업그레이드 Argus Hold → Buy
2022-06-14 다운그레이드 UBS Buy → Neutral
2022-02-11 업그레이드 DZ Bank Sell → Hold
2021-12-07 다운그레이드 Jefferies Buy → Hold
2021-08-12 재개 JP Morgan Overweight
2021-04-12 다운그레이드 Argus Buy → Hold
2021-03-16 업그레이드 Jefferies Hold → Buy
2021-02-25 업그레이드 UBS Neutral → Buy
2021-01-15 개시 Deutsche Bank Buy
2020-12-07 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-11-30 업그레이드 UBS Sell → Neutral
2020-11-11 업그레이드 HSBC Securities Reduce → Hold
2020-09-29 개시 Berenberg Buy
2019-11-22 개시 SVB Leerink Outperform
2019-10-25 업그레이드 Liberum Hold → Buy
2019-04-02 다운그레이드 UBS Neutral → Sell
2019-02-05 개시 Exane BNP Paribas Outperform
2019-01-25 업그레이드 Shore Capital Hold → Buy
2018-12-11 재개 Jefferies Hold
2018-10-09 개시 Guggenheim Buy
2018-08-16 다운그레이드 Jefferies Buy → Hold
2018-03-19 업그레이드 Jefferies Hold → Buy
2018-02-06 재확인 Leerink Partners Mkt Perform
2018-02-05 재확인 Bernstein Outperform
2018-01-18 재확인 Leerink Partners Mkt Perform
2017-12-29 업그레이드 JP Morgan Neutral → Overweight
2017-10-16 업그레이드 Credit Suisse Neutral → Outperform
2017-09-25 업그레이드 Exane BNP Paribas Neutral → Outperform
2017-09-22 업그레이드 Bernstein Mkt Perform → Outperform
모두보기

아스트라제네카 ADR 주식(AZN)의 최신 뉴스

pulisher
01:00 AM

Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight - GlobeNewswire Inc.

01:00 AM
pulisher
12:56 PM

Press Release Distribution & PR Platform - ACCESS Newswire

12:56 PM
pulisher
11:02 AM

Omeprazole Market Is Booming Worldwide 2025-2032 | Astrazeneca Plc., Sandoz, Inc., Mylan N.V. - openPR.com

11:02 AM
pulisher
09:40 AM

Should You Buy, Sell Or Hold AstraZeneca Stock Before Q1 Earnings? - Barchart.com

09:40 AM
pulisher
09:12 AM

AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial - Seeking Alpha

09:12 AM
pulisher
08:21 AM

Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? - Yahoo

08:21 AM
pulisher
08:05 AM

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients - Yahoo Finance

08:05 AM
pulisher
07:51 AM

ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival Versus. THP As 1st-Line Therapy For Patients With HER2+ Metastatic Breast Cancer - marketscreener.com

07:51 AM
pulisher
05:30 AM

AstraZeneca (AZN) Highlights Promising Trial Results for Enhertu in Breast Cancer Treatment | AZN Stock News - GuruFocus

05:30 AM
pulisher
05:14 AM

AstraZeneca Touts Positive Survival Data for Enhertu Combo in Broad Breast Cancer Population - marketscreener.com

05:14 AM
pulisher
03:26 AM

AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Shows High-level Results in Late-stage Trial - marketscreener.com

03:26 AM
pulisher
Apr 18, 2025

Vasculitis Market Overall Study Report 2025-2032 | AstraZeneca - openPR.com

Apr 18, 2025
pulisher
Apr 17, 2025

AstraZeneca Unit Hit With Antitrust Suit Over Soliris - Law360

Apr 17, 2025
pulisher
Apr 17, 2025

AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly - Bloomberg Law News

Apr 17, 2025
pulisher
Apr 17, 2025

AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris - Reuters

Apr 17, 2025
pulisher
Apr 17, 2025

AstraZeneca Unit Faces US Class Action Lawsuit Alleging Misuse of Soliris Patent - marketscreener.com

Apr 17, 2025
pulisher
Apr 16, 2025

AstraZeneca Should Get Fired Worker’s Vaccine Bias Case Trimmed - Bloomberg Law News

Apr 16, 2025
pulisher
Apr 16, 2025

BNP Paribas Exane sets AstraZeneca stock to outperform, PT at GBP115 - Investing.com UK

Apr 16, 2025
pulisher
Apr 15, 2025

Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey

Apr 15, 2025
pulisher
Apr 15, 2025

European pharma companies issue demands to stay in EU ahead of expected US tariffs - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly - insights.citeline.com

Apr 15, 2025
pulisher
Apr 15, 2025

AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib - Medical Dialogues

Apr 15, 2025
pulisher
Apr 14, 2025

Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires? - Yahoo Finance

Apr 14, 2025
pulisher
Apr 14, 2025

The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Nasdaq

Apr 14, 2025
pulisher
Apr 13, 2025

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

Apr 13, 2025
pulisher
Apr 12, 2025

AstraZeneca : India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output - marketscreener.com

Apr 12, 2025
pulisher
Apr 11, 2025

NICE recommends new combination breast cancer drug - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

astrazeneca shareholders approve all resolutions at agm - Investing.com

Apr 11, 2025
pulisher
Apr 11, 2025

Astrazeneca PLC Says All Resolutions Passed At AGM - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

AstraZeneca’s AGM Approves All Resolutions, Marks Board Changes - TipRanks

Apr 11, 2025
pulisher
Apr 11, 2025

Drug Tariffs Will Harm Patients, AstraZeneca Chairman Says - Bloomberg.com

Apr 11, 2025
pulisher
Apr 10, 2025

AstraZeneca (AZN) Gains Momentum with EU Drug Approvals - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle - Proactive financial news

Apr 10, 2025
pulisher
Apr 10, 2025

AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that - Proactive Investors

Apr 10, 2025
pulisher
Apr 10, 2025

GLP-1 Market Top PlayersAstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech. - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now? - Yahoo

Apr 10, 2025
pulisher
Apr 10, 2025

AstraZeneca (AZN) Gains EU Nod for Imfinzi Combo in NSCLC Treatm - GuruFocus

Apr 10, 2025
pulisher
Apr 10, 2025

AstraZeneca (AZN) Gains EU Approval for Expanded Enhertu Use in Breast Cancer - GuruFocus

Apr 10, 2025
pulisher
Apr 09, 2025

AstraZeneca Settles Covid-Shot Suit With Christian Salesman - Bloomberg Law News

Apr 09, 2025
pulisher
Apr 09, 2025

AstraZeneca Blocks Generics Ahead Of Patent Dispute - Law360

Apr 09, 2025
pulisher
Apr 09, 2025

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - Mitrade

Apr 09, 2025
pulisher
Apr 09, 2025

AstraZeneca stock touches 52-week low at $61.76 - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

AstraZeneca stock touches 52-week low at $61.76 By Investing.com - Investing.com India

Apr 09, 2025
pulisher
Apr 09, 2025

UK Regulator Approves Expanded Use of AstraZeneca's Targeted Cancer Therapy - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

UK Approves Indication Extension for AstraZeneca-Daiichi Sankyo's Cancer Drug Enhertu - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Barclays Keeps AstraZeneca at Overweight on Potential to Withstand Tariff Storm - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

AstraZeneca (AZN) Prepares for Upcoming Earnings Amid Stock Decl - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca - Yahoo

Apr 09, 2025
pulisher
Apr 09, 2025

FTSE 100 sinks as tariffs kick in with 104% for China; AstraZeneca and GSK slumpMarket Report - Proactive financial news

Apr 09, 2025
pulisher
Apr 09, 2025

AstraZeneca's Camizestrant Shows Promise in SERENA-6 Breast Canc - GuruFocus

Apr 09, 2025
pulisher
Apr 09, 2025

Trump inflicts £14bn blow to the UK drug sector with tariff threat - Proactive Investors

Apr 09, 2025

아스트라제네카 ADR (AZN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
자본화:     |  볼륨(24시간):